TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30649897

Group type: EXPERIMENTAL
Intervention: Stair climbing exercise 'snacks' (3 bouts/day of vigorously ascending a 3‐flight stairwell, 60 steps, 3 days/week for 6 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nontraining control group
Number of subjects: 12
Study: 27518486

Group type: EXPERIMENTAL
Intervention: Sebacoyl dinalbuphine ester (SDE) injection (150 mg/2 mL)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 25468629

Group type: EXPERIMENTAL
Intervention: Pterygoid disjunction
Number of subjects: 38

Group type: COMPARATOR
Intervention: Third molar socket disjunction
Number of subjects: 38
Study: 23411106

Group type: EXPERIMENTAL
Intervention: Elevated white blood cell count (WBCc) at admission
Number of subjects: 13678

Group type: EXPERIMENTAL
Intervention: WBCc
Number of subjects: 13678
Study: 22005366

Group type: EXPERIMENTAL
Intervention: Extra Dartos pouch technique
Number of subjects: 159

Group type: COMPARATOR
Intervention: Classic sub-Dartos pouch technique
Number of subjects: 159
Study: 19775040

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral catheter placement
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nerve stimulation-guided femoral catheter placement
Number of subjects: 45
Study: 18156032

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (fluid diet and either polyethylene glycol or sodium phosphate)
Number of subjects: 1431

Group type: COMPARATOR
Intervention: No mechanical bowel preparation (normal meal the day before surgery)
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation
Number of subjects: 1431

Group type: COMPARATOR
Intervention: No mechanical bowel preparation
Number of subjects: 1431
Study: 15462154

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma + atropine + pralidoxime
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pralidoxime
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Number of subjects: 33
Study: 11906441

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 0
Study: 9731794

Group type: EXPERIMENTAL
Intervention: FUT-175 (2 mg/kg per hour) during cardiopulmonary bypass (group F)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (untreated patients, group C)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hypoxic myocytes (group 2H)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normoxic myocytes (group N)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FUT-175 addition to hypoxic myocytes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coincubation of endothelial cells and myocytes (group 2H)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normoxic coincubation (group N)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Coincubation with anti-interleukin-6 monoclonal antibody
Number of subjects: 20
Study: 7800195

Group type: EXPERIMENTAL
Intervention: Ketoprofen lysine salt (80 mg granular sachet)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2897812

Group type: EXPERIMENTAL
Intervention: Bevantolol (100-300 mg bid)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Propranolol (80-240 mg bid)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Bevantolol
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25-50 mg bid)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Both beta‐adrenoceptor antagonists
Number of subjects: 266
Study: 1218150

Group type: EXPERIMENTAL
Intervention: 50 mulitre/kg of Althesin for induction of anaesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: 100 mulitre/kg of Althesin for induction of anaesthesia
Number of subjects: 30
Study: 31286802

Group type: EXPERIMENTAL
Intervention: Avelumab (anti-PD-L1 antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avelumab (as second-line treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avelumab (as maintenance therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avelumab (in combination with chemotherapy)
Number of subjects: 0
Study: 28332720

Group type: EXPERIMENTAL
Intervention: Luliconazole 5% nail solution, applied once daily for 48 weeks
Number of subjects: 293

Group type: COMPARATOR
Intervention: Vehicle, applied once daily for 48 weeks
Number of subjects: 293
Study: 26469083

Group type: EXPERIMENTAL
Intervention: Weight-based RBV (1,000 or 1,200 mg/day)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Flat-dose RBV (800 mg/day)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Weight-based RBV (≥13 mg/kg/day)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Weight-based RBV (<13 mg/kg/day)
Number of subjects: 493
Study: 24695944

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based participatory research project
Number of subjects: 0
Study: 22050862

Group type: EXPERIMENTAL
Intervention: Radiographic evaluation with clinical notes
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Clinical notes evaluation
Number of subjects: 51
Study: 19559401

Group type: EXPERIMENTAL
Intervention: Suppression
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Acceptance
Number of subjects: 89

Group type: COMPARATOR
Intervention: No-regulation control
Number of subjects: 89
Study: 17453398

Group type: EXPERIMENTAL
Intervention: Indomethacin 3 times daily for 7 days
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Rofecoxib twice daily for 7 days
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo daily for 7 days
Number of subjects: 186
Study: 12967321

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Statin therapy (combined pravastatin and simvastatin)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 55
Study: 11523255

Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF) 20 mg per day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Methotrexate (MTX) 15 mg per week
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Leflunomide (LEF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 81
Study: 9762745

Group type: EXPERIMENTAL
Intervention: Chiropractic
Number of subjects: 323

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 323
Study: 7937251

Group type: EXPERIMENTAL
Intervention: Structured exercise program of walking and support group meetings
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 14
Study: 3069466

Group type: EXPERIMENTAL
Intervention: Labetalol (200-400 mg twice daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nifedipine (10-20 mg three times daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Labetalol and Nifedipine
Number of subjects: 11
Study: 29864071

Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) warm‐up program
Number of subjects: 2265

Group type: COMPARATOR
Intervention: Previous ASI
Number of subjects: 2265

Group type: COMPARATOR
Intervention: Participation in basketball versus soccer
Number of subjects: 2265
Study: 26324401

Group type: EXPERIMENTAL
Intervention: Glycopyrronium bromide 50 µg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium bromide 18 µg once daily
Number of subjects: 0
Study: 24036725

Group type: EXPERIMENTAL
Intervention: Mg ion‐incorporated titanium implants
Number of subjects: 114

Group type: COMPARATOR
Intervention: RBM surface titanium implants
Number of subjects: 114
Study: 21235752

Group type: EXPERIMENTAL
Intervention: Shoulder function training (3 × 20 min sessions with training supervision)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Advice to stay physically active (Control group)
Number of subjects: 100
Study: 18714252

Group type: EXPERIMENTAL
Intervention: Carbohydrate-glycerol (CG) beverage
Number of subjects: 10

Group type: COMPARATOR
Intervention: Carbohydrate (C) beverage
Number of subjects: 10
Study: 17961107

Group type: EXPERIMENTAL
Intervention: HAART regimen with two NRTIs (didanosine + stavudine) plus NNRTI (efavirenz)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: HAART regimen with two NRTIs (didanosine + stavudine) plus PI (nelfinavir)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: HAART regimen with two NRTIs (didanosine + stavudine) plus both NNRTI (efavirenz) and PI (nelfinavir)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: HAART regimen with two NRTIs (didanosine + stavudine) plus NNRTI (efavirenz) or PI (nelfinavir)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: HAART regimen with four-drug, three-class regimens
Number of subjects: 153
Study: 15047441

Group type: EXPERIMENTAL
Intervention: Antenatal gymnastics (twice a week, 45 min sessions, 60% of maximum heart frequency)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no antenatal gymnastics)
Number of subjects: 50
Study: 10742359

Group type: EXPERIMENTAL
Intervention: Encounter-based immunization prompting system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no prompting system)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre- and post-intervention knowledge scores for intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre- and post-intervention knowledge scores for control group
Number of subjects: 0
Study: 8732310

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100‐300 mg/day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 1549538

Group type: EXPERIMENTAL
Intervention: Ofloxacin 100 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ofloxacin 600 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3886500

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31880235

Group type: EXPERIMENTAL
Intervention: E-cigarette message exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Persuasive messages
Number of subjects: 0
Study: 30255188

Group type: EXPERIMENTAL
Intervention: Coloured rice polyphenol extracts (PE) from purple rice at 10, 20, 50, 100, 200 and 500 μg mL‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coloured rice polyphenol extracts (PE) from red rice at 10, 20, 50, 100, 200 and 500 μg mL‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coloured rice polyphenol extracts (PE) from brown rice at 10, 20, 50, 100, 200 and 500 μg mL‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brown rice PE at 50 μg mL‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red rice PE at 50 μg mL‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purple rice PE at 50 μg mL‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coloured rice polyphenol extracts (PE)
Number of subjects: 0
Study: 27521719

Group type: EXPERIMENTAL
Intervention: 12 SQ HDM SLIT-tablet
Number of subjects: 1482
Study: 24798210

Group type: EXPERIMENTAL
Intervention: West Wales ADR Profile for Respiratory Medicine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study: 22486815

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 131
Study: 20169656

Group type: EXPERIMENTAL
Intervention: Optimal treatment including endoscopic haemostatic and high-dose intravenous proton-pump inhibitors
Number of subjects: 140
Study: 18571502

Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16100643

Group type: EXPERIMENTAL
Intervention: Sharp excision of endometriosis
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham surgical excision (control)
Number of subjects: 29
Study: 12367547

Group type: EXPERIMENTAL
Intervention: EMLA (topical anaesthetic)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 10602525

Group type: EXPERIMENTAL
Intervention: MRI evidence of cord edema
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Presence of hemorrhage
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Cord hemorrhage, contusion, and edema on MRI
Number of subjects: 499
Study: 8952311

Group type: EXPERIMENTAL
Intervention: ARX model
Number of subjects: 10

Group type: COMPARATOR
Intervention: MTA model
Number of subjects: 10
Study: 2009042

Group type: EXPERIMENTAL
Intervention: Sitting with elbow in 90 degree flexion
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Sitting with elbow in full extension
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Standing with elbow in 90 degree flexion
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Standing with elbow in full extension
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Males (all positions)
Number of subjects: 61
Study: 7087973

Group type: EXPERIMENTAL
Intervention: HDM extract
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30871542

Group type: COMPARATOR
Intervention: 1000 IU/day of vitamin D
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 2000 IU/day of vitamin D
Number of subjects: 50
Study: 30397709

Group type: EXPERIMENTAL
Intervention: Natural Cycle
Number of subjects: 332

Group type: COMPARATOR
Intervention: HRT Cycle
Number of subjects: 332
Study: 26970946

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: No therapeutic hypothermia treatment (control)
Number of subjects: 23
Study: 25252624

Group type: EXPERIMENTAL
Intervention: TNFα polymorphism "‐1031"
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: TNFα polymorphism "‐863"
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: TNFα G‐A‐G haplotype
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: TNFα "‐1031" minor allele
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: TNFα "‐863" minor allele
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: TNFα "‐1031" and IL4R Ser503Pro interaction
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: TNFα "‐1031" and IL10 "‐1082" interaction
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: TNFα "‐863" and IL10 "‐1082" interaction
Number of subjects: 542
Study: 22537984

Group type: EXPERIMENTAL
Intervention: 15 μg Sanofi-Pasteur vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 μg CSL vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 μg dosage
Number of subjects: 0
Study: 20231231

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 2701

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 2701
Study: 17686209

Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paracetamol 15 mg/kg
Number of subjects: 0
Study: 16330788

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus 5 to 7 plasma exchanges of 50 mL per kg of body weight of 5% human serum albumin for 10 days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 104
Study: 11974556

Group type: EXPERIMENTAL
Intervention: 1 mg/day 17 beta-estradiol combined with 5 or 10 mg/day dydrogesterone
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: 2 mg/day 17 beta-estradiol combined with 10 or 20 mg/day dydrogesterone
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: 1 mg/day 17 beta-estradiol
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Higher doses of dydrogesterone
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: All groups (irrespective of estradiol or dydrogesterone dose)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 579
Study: 9952150

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.075 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.5 mg
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (various doses)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (0.0 mg intrathecal morphine)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.0-0.5 mg)
Number of subjects: 108
Study: 7567589

Group type: EXPERIMENTAL
Intervention: 65% tilt biphasic pulse
Number of subjects: 15

Group type: COMPARATOR
Intervention: 50% tilt biphasic pulse
Number of subjects: 15
Study: 2190015

Group type: EXPERIMENTAL
Intervention: Aztreonam (AZT) + Clindamycin (CLDM)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Amikacin (AMK) + Aztreonam (AZT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Clindamycin (CLDM) + Amikacin (AMK)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aztreonam (AZT) + Clindamycin (CLDM) in patients with neutrophil counts < 500/microliters
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Amikacin (AMK) + Aztreonam (AZT) in patients with neutrophil counts < 500/microliters
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Clindamycin (CLDM) + Amikacin (AMK) in patients with neutrophil counts < 500/microliters
Number of subjects: 160
Study: 859123

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Beer
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Bourbon
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Soft drinks
Number of subjects: 249
Study: 30856182

Group type: EXPERIMENTAL
Intervention: siPRBCs (stored for over 21 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: fPRBCs (stored for less than 14 days)
Number of subjects: 19
Study: 28646901

Group type: EXPERIMENTAL
Intervention: Ezetimibe add-on therapy (10 mg)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Double-dose statin therapy
Number of subjects: 109
Study: 25636992

Group type: EXPERIMENTAL
Intervention: Partial body weight supported treadmill training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Over ground walking (control)
Number of subjects: 30
Study: 23292315

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficient (serum 25(OH)D ≤32 ng/mL)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vitamin D sufficient (serum 25(OH)D >32 ng/mL)
Number of subjects: 28
Study: 22286627

Group type: EXPERIMENTAL
Intervention: Patient-rated wrist evaluation (PRWE) questionnaire
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Grip strength measurement
Number of subjects: 64
Study: 19672935

Group type: EXPERIMENTAL
Intervention: Folic acid (400 microg daily)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 5-MTHF (daily)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 17082284

Group type: EXPERIMENTAL
Intervention: 4 percent articaine hydrochloride with 1:200,000 epinephrine (A200)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: 4 percent articaine hydrochloride with 1:100,000 epinephrine (A100)
Number of subjects: 126

Group type: COMPARATOR
Intervention: 4 percent articaine hydrochloride without epinephrine (Aw/o)
Number of subjects: 126
Study: 15047680

Group type: EXPERIMENTAL
Intervention: Vitamin C (515 mg/day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Antioxidant mixture (515 mg vitamin C, 371 mg alpha-tocopherol, 171 mg gamma-tocopherol, 252 mg mixed tocotrienols, and 95 mg alpha-lipoic acid)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 12228852

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (angiotensin receptor blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol (beta-blocker)
Number of subjects: 0
Study: 9688035

Group type: EXPERIMENTAL
Intervention: Intensive neck/shoulder training programme
Number of subjects: 77

Group type: COMPARATOR
Intervention: Lighter intensity neck/shoulder training programme
Number of subjects: 77
Study: 8135388

Group type: EXPERIMENTAL
Intervention: Atracurium, 0.5 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pancuronium, 0.1 mg/kg
Number of subjects: 20
Study: 2800992

Group type: EXPERIMENTAL
Intervention: Indomethacin, 0.8 mg/kg i.v. preoperatively, followed by 100 mg rectally 8-hourly for 3 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 41
Study: 578400

Group type: EXPERIMENTAL
Intervention: Clotrimazole 1% solution
Number of subjects: 80

Group type: COMPARATOR
Intervention: Haloprogin 1% solution
Number of subjects: 80
Study: 31494820

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 46
Study: 31513877

Group type: EXPERIMENTAL
Intervention: Volitional stepping under unstable conditions (VOL + US)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Volitional stepping (VOL)
Number of subjects: 51
Study: 28271430

Group type: EXPERIMENTAL
Intervention: ASPIRE-Group
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: ASPIRE-Phone
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: MOVE!
Number of subjects: 332
Study: 26169621

Group type: EXPERIMENTAL
Intervention: CAU + BREATH
Number of subjects: 150

Group type: COMPARATOR
Intervention: CAU alone
Number of subjects: 150
Study: 23460682

Group type: EXPERIMENTAL
Intervention: Postpartum anxiety screening and care model intervention
Number of subjects: 1123

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1123
Study: 22480102

Group type: EXPERIMENTAL
Intervention: Ribavirin with supportive management
Number of subjects: 100

Group type: COMPARATOR
Intervention: Supportive therapy only (Control)
Number of subjects: 100
Study: 20112821

Group type: EXPERIMENTAL
Intervention: Yoga training (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 120
Study: 16736390

Group type: EXPERIMENTAL
Intervention: Family intervention followed by a support group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16121901

Group type: EXPERIMENTAL
Intervention: Tailored newsletters and specialized cleaning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored newsletters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 11291803

Group type: EXPERIMENTAL
Intervention: AV junction ablation and VVIR pacemaker
Number of subjects: 50